Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.

Autor: Nguyen CN; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Christopher.Nguyen42@gmail.com., Iyer SP; Department of Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Duvic M; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Barde PJ; Rhizen Pharmaceuticals AG, Basel, Switzerland., Nair A; Rhizen Pharmaceuticals AG, Basel, Switzerland., Routhu KV; Rhizen Pharmaceuticals AG, Basel, Switzerland., Huen AO; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jazyk: angličtina
Zdroj: Investigational new drugs [Invest New Drugs] 2023 Apr; Vol. 41 (2), pp. 350-355. Date of Electronic Publication: 2023 Apr 01.
DOI: 10.1007/s10637-022-01315-6
Abstrakt: Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may be refractory to multiple systemic treatments. These cases can be difficult to achieve and maintain complete response and there is a need for novel therapeutics. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway by Tenalisib presents one such emerging drug. We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monotherapy.
(© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: